







,

,

,

,

,

, and

.

In one aspect, the present disclosure refers to a compound of Formula (I-A):


(I-A)

or a pharmaceutically acceptable salt thereof, wherein:

Ring A1 is pyrimidinyl or pyridyl;

R^{1A} is halogen;

R^{1B} is halogen or absent;

R^2 is a C1-C6 alkyl or a C1-C6 haloalkyl;

R^3 is a C1-C6 alkyl, a C1-C6 haloalkyl, or a C3-C6 cycloalkyl optionally substituted with 1 or 2 substituents independently selected from fluoro and C1-C6 alkyl;

R^4 is independently selected from the group consisting of: C1-C6 alkyl optionally substituted with $-NR^AR^B$, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxyl, cyano, $-CO_2H$, $-NR^AR^B$, $-C(=O)NR^CR^D$, $-SO_2(NR^ER^F)$, $-SO_2$(C1-C6 alkyl), $-S(=O)(=NH)$(C1-C6 alkyl), $-C(=O)$(C1-C6 alkyl), $-CO_2$(C1-C6 alkyl), 5-6 membered heteroaryl optionally substituted with C1-C6 alkyl, 3-6 membered heterocyclyl optionally substituted with 1 or 2 independently selected R^G, and 3-6 membered cycloalkyl optionally substituted with 1 or 2 independently selected R^G;

wherein R^4 is bonded to the position of Ring A1 that is *para* to the N atom of the urea moiety;


each R^A, R^{A1}, R^B, R^{B1}, R^C, R^{C1}, R^D, R^{D1}, R^E, and R^F is independently hydrogen, 4-6 membered heterocyclyl, C1-C6 haloalkyl, 3-6 membered cycloalkyl optionally substituted with hydroxyl, or C1-C6 alkyl optionally substituted with 1-2 substituents independently selected from hydroxyl, 3-6 membered cycloalkyl, $-SO_2$(C1-C6 alkyl), and $-SO_2(NH_2)$; or

R^C and R^D, together with the nitrogen atom to which they are attached form a 4-6 membered heterocyclyl; and

each R^G is independently selected from the group consisting of: fluoro, cyano, hydroxyl, C1-C6 alkoxy, $-NR^{A1}R^{B1}$, $-C(=O)NR^{C1}R^{D1}$, $-CO_2$(C1-C6 alkyl), C1-C6 haloalkyl, C3-C6 cycloalkyl, $-CO_2H$, and C1-C6 alkyl optionally substituted with hydroxyl.

WHAT IS CLAIMED IS:

1. A compound of Formula (I-A):



(I-A)

or a pharmaceutically acceptable salt thereof, wherein:

Ring A1 is pyrimidinyl or pyridyl;

R^{1A} is halogen;

R^{1B} is halogen or absent;

R^2 is a C1-C6 alkyl or a C1-C6 haloalkyl;

R^3 is a C1-C6 alkyl, a C1-C6 haloalkyl, or a C3-C6 cycloalkyl optionally substituted with 1 or 2 substituents independently selected from fluoro and C1-C6 alkyl;

R^4 is independently selected from the group consisting of: C1-C6 alkyl optionally substituted with $-NR^AR^B$, C1-C6 alkoxy, C1-C6 haloalkyl, hydroxyl, cyano, $-CO_2H$, $-NR^AR^B$, $-C(=O)NR^CR^D$, $-SO_2(NR^ER^F)$, $-SO_2$(C1-C6 alkyl), -S(=O)(=NH)(C1-C6 alkyl), -C(=O)(C1-C6 alkyl), $-CO_2$(C1-C6 alkyl), 5-6 membered heteroaryl optionally substituted with C1-C6 alkyl, 3-6 membered heterocyclyl optionally substituted with 1 or 2 independently selected R^G, and 3-6 membered cycloalkyl optionally substituted with 1 or 2 independently selected R^G;

wherein R^4 is bonded to the position of Ring A1 that is *para* to the N atom of the urea moiety;

each R^A, R^{A1}, R^B, R^{B1}, R^C, R^{C1}, R^D, R^{D1}, R^E, and R^F is independently hydrogen, 4-6 membered heterocyclyl, C1-C6 haloalkyl, 3-6 membered cycloalkyl optionally substituted with hydroxyl, or C1-C6 alkyl optionally substituted with 1-2 substituents independently selected from hydroxyl, 3-6 membered cycloalkyl, $-SO_2$(C1-C6 alkyl), and $-SO_2(NH_2)$; or

R^C and R^D, together with the nitrogen atom to which they are attached form a 4-6 membered heterocyclyl; and

each R^G is independently selected from the group consisting of: fluoro, cyano, hydroxyl, C1-C6 alkoxy, $-NR^{A1}R^{B1}$, $-C(=O)NR^{C1}R^{D1}$, $-CO_2$(C1-C6 alkyl), C1-C6 haloalkyl, C3-C6 cycloalkyl, $-CO_2H$, and C1-C6 alkyl optionally substituted with hydroxyl.

2. The compound of claim 1, wherein R^{1A} is selected from fluoro and chloro.

3. The compound of claim 1 or 2, wherein R^{1A} is fluoro.

4. The compound of any one of claims 1-3, wherein R^{1B} is halogen.

5. The compound of any one of claims 1-4, wherein R^{1B} is fluoro.

6. The compound of any one of claims 1-5, wherein R^2 is a C1-C6 alkyl.


7. The compound of any one of claims 1-6, wherein R^2 is methyl.


8. The compound of any one of claims 1-7, wherein R^3 is a C1-C6 haloalkyl.

9. The compound of any one of claims 1-8, wherein R^3 is difluoromethyl.

10. The compound of any one of claims 1-8, wherein R^3 is trifluoromethyl.

11. The compound of any one of claims 1-10, wherein Ring A1 is pyrimidinyl.

12. The compound of any one of claims 1-11, wherein 

is 


.


13. The compound of any one of claims 1-10, wherein Ring A1 is pyridyl.

14. The compound of any one of claims 1-13, wherein R^4 is $-NR^AR^B$.

15. The compound of any one of claims 1-14, wherein one of R^A and R^B is hydrogen or C1-C6 alkyl and the other of R^A and R^B is hydrogen, 4-6 membered heterocyclyl, C1-C6 haloalkyl, 3-6 membered cycloalkyl optionally substituted with hydroxyl, or C1-C6 alkyl optionally substituted with 1-2 substituents independently selected from hydroxyl, 3-6 membered cycloalkyl, or $-SO_2$(C1-C6 alkyl).

16. The compound of any one of claims 1-15, wherein one of R^A and R^B is hydrogen and the other of R^A and R^B is hydrogen or C1-C6 alkyl.


17. The compound of any one of claims 1-12, wherein 

is 

, wherein: R^{4B} is selected from $-NR^AR^B$ and 4-6 membered heterocyclyl comprising one nitrogen ring member and optionally substituted with 1-2 independently selected R^{G1}; wherein R^{G1} is selected from fluoro, hydroxyl, and C1-C6 alkyl.


18. A compound selected from the group consisting of the compounds in Table A, Table B, and Table C, Table D, or a pharmaceutically acceptable salt thereof.

19. A compound which is 1-(2-aminopyrimidin-5-yl)-3-(1-(5,7-difluoro-3-methylbenzofuran-2-yl)-2,2,2-trifluoroethyl)urea, or a pharmaceutically acceptable salt thereof, having the structure:




or a pharmaceutically acceptable salt thereof.

20. The compound of claim 19, wherein the compound is (S)-1-(2-aminopyrimidin-5-yl)-3-(1-(5,7-difluoro-3-methylbenzofuran-2-yl)-2,2,2-trifluoroethyl)urea, or a pharmaceutically acceptable salt thereof, having the structure:



or a pharmaceutically acceptable salt thereof.

21. The compound of claim 19, wherein the compound is (R)-1-(2-aminopyrimidin-5-yl)-3-(1-(5,7-difluoro-3-methylbenzofuran-2-yl)-2,2,2-trifluoroethyl)urea, or a pharmaceutically acceptable salt thereof, having the structure:



or a pharmaceutically acceptable salt thereof.

22. The compound of Claim 19, wherein the compound is 1-(2-aminopyrimidin-5-yl)-3-(1-(5,7-difluoro-3-methylbenzofuran-2-yl)-2,2,2-trifluoroethyl)urea.


23. The compound of Claim 20 wherein the compound is (S)-1-(2-aminopyrimidin-5-yl)-3-(1-(5,7-difluoro-3-methylbenzofuran-2-yl)-2,2,2-trifluoroethyl)urea.

24. The compound of Claim 21, wherein the compound is (R)-1-(2-aminopyrimidin-5-yl)-3-(1-(5,7-difluoro-3-methylbenzofuran-2-yl)-2,2,2-trifluoroethyl)urea.

25. A pharmaceutical composition comprising a compound of any one of claims 1-24, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

26. Use of a compound of any one of claims 1-24, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 25 in the manufacture of a medicament for treating cancer.


27. Use of a compound in the manufacture of a medicament for treating a solid tumor, wherein the solid tumor has one or more mutations in PI3Kα, and wherein the compound is 1-(2-aminopyrimidin-5-yl)-3-(1-(5,7-difluoro-3-methylbenzofuran-2-yl)-2,2,2-trifluoroethyl)urea, or a pharmaceutically acceptable salt thereof, having the structure:



or a pharmaceutically acceptable salt thereof.


28. Use of a compound in the manufacture of a medicament for treating cancer, wherein the cancer has one or more mutations in PI3Kα, wherein in the cancer is selected from

breast cancer, endometrial cancer, bladder cancer, head and neck cancer, and wherein the compound is 1-(2-aminopyrimidin-5-yl)-3-(1-(5,7-difluoro-3-methylbenzofuran-2-yl)-2,2,2-trifluoroethyl)urea, or a pharmaceutically acceptable salt thereof, having the structure:



or a pharmaceutically acceptable salt thereof.

29. The use of claim 27 or 28, wherein the compound is (R)-1-(2-aminopyrimidin-5-yl)-3-(1-(5,7-difluoro-3-methylbenzofuran-2-yl)-2,2,2-trifluoroethyl)urea, or a pharmaceutically acceptable salt thereof, having the structure:



or a pharmaceutically acceptable salt thereof.

30. The use of claim 27 or 28, wherein the compound is 1-(2-aminopyrimidin-5-yl)-3-(1-(5,7-difluoro-3-methylbenzofuran-2-yl)-2,2,2-trifluoroethyl)urea.

31. The use of claim 29, wherein the compound is (R)-1-(2-aminopyrimidin-5-yl)-3-(1-(5,7-difluoro-3-methylbenzofuran-2-yl)-2,2,2-trifluoroethyl)urea.

32. The use of any one of claims 27-31, wherein the one or more mutations in PI3Kα are selected from the group consisting of: E542A, E542G, E542K, E542Q, E542V, E545A, E545D, E545G, E545K, E545Q, M1043I, M1043L, M1043T, M1043V, H1047L, H1047Q, H1047R, H1047Y, and G1049R, and combinations thereof.